The stock of Concert Pharmaceuticals Inc (NASDAQ:CNCE) hit a new 52-week low and has $6.94 target or 11.00% below today’s $7.80 share price. The 5 months bearish chart indicates high risk for the $163.43 million company. The 1-year low was reported on Nov, 1 by Barchart.com. If the $6.94 price target is reached, the company will be worth $17.98 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 42,414 shares traded hands. Concert Pharmaceuticals Inc (NASDAQ:CNCE) has declined 41.43% since March 30, 2016 and is downtrending. It has underperformed by 44.44% the S&P500.
Analysts await Concert Pharmaceuticals Inc (NASDAQ:CNCE) to report earnings on November, 3. They expect $-0.63 earnings per share, down 61.54% or $0.24 from last year’s $-0.39 per share. After $-0.60 actual earnings per share reported by Concert Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 5.00% negative EPS growth.
Concert Pharmaceuticals Inc (NASDAQ:CNCE) Ratings Coverage
Out of 7 analysts covering Concert Pharmaceuticals (NASDAQ:CNCE), 6 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 86% are positive. Concert Pharmaceuticals has been the topic of 9 analyst reports since August 12, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating by Roth Capital given on Tuesday, September 22. The stock of Concert Pharmaceuticals Inc (NASDAQ:CNCE) has “Neutral” rating given on Monday, November 9 by UBS. Aegis Capital initiated Concert Pharmaceuticals Inc (NASDAQ:CNCE) rating on Wednesday, September 9. Aegis Capital has “Buy” rating and $26 price target. TH Capital maintained the stock with “Buy” rating in Tuesday, September 22 report. JMP Securities maintained Concert Pharmaceuticals Inc (NASDAQ:CNCE) on Wednesday, March 9 with “Market Outperform” rating. The stock of Concert Pharmaceuticals Inc (NASDAQ:CNCE) earned “Buy” rating by Stifel Nicolaus on Friday, July 1. Brean Capital initiated Concert Pharmaceuticals Inc (NASDAQ:CNCE) rating on Wednesday, August 12. Brean Capital has “Buy” rating and $21 price target.
According to Zacks Investment Research, “Concert Pharmaceuticals Inc. is a biopharmaceutical company. It is focused on applying its DCE Platform (R) to create novel small molecule drugs. The Company manufactures drugs in various therapeutic areas such as hot flashes, HIV, renal hepatic, neuropathic pain, MRSA infection, and schizophrenia, multiple tumors, and hyperparathyroidism. Concert Pharmaceuticals Inc. is based in United States.”
Insitutional Activity: The institutional sentiment increased to 1.39 in Q2 2016. Its up 0.36, from 1.03 in 2016Q1. The ratio increased, as 8 funds sold all Concert Pharmaceuticals Inc shares owned while 25 reduced positions. 11 funds bought stakes while 35 increased positions. They now own 13.09 million shares or 2.13% less from 13.37 million shares in 2016Q1.
California Pub Employees Retirement last reported 0% of its portfolio in the stock. Rhenman And Prtnrs Asset Mngmt owns 30,099 shares or 0.06% of their US portfolio. Credit Suisse Ag, a Switzerland-based fund reported 34,894 shares. Nationwide Fund Advisors has 0% invested in the company for 37,420 shares. Alps holds 0% of its portfolio in Concert Pharmaceuticals Inc (NASDAQ:CNCE) for 31,210 shares. Bvf Il owns 2.76M shares or 6.59% of their US portfolio. Proshare Advsr Limited Liability Corp last reported 0% of its portfolio in the stock. Tiaa Cref Mngmt Ltd accumulated 0% or 106,406 shares. Renaissance Tech Ltd Liability has 161,300 shares for 0% of their US portfolio. The New York-based Spark Investment Mgmt Ltd Limited Liability Company has invested 0.29% in Concert Pharmaceuticals Inc (NASDAQ:CNCE). Jacobs Levy Equity Management Inc last reported 26,836 shares in the company. The New York-based Springbok Management Ltd Llc has invested 0% in Concert Pharmaceuticals Inc (NASDAQ:CNCE). Senzar Asset Lc holds 0% or 800,788 shares in its portfolio. Mufg Americas Holdg Corp reported 2,287 shares or 0% of all its holdings. Geode Cap Management Ltd Liability Co last reported 140,469 shares in the company.
More notable recent Concert Pharmaceuticals Inc (NASDAQ:CNCE) news were published by: Marketwatch.com which released: “/quotes/zigman/3870025/realtime” on February 14, 2014, also Businesswire.com with their article: “Concert Pharmaceuticals Presents Poster at 2016 North American Cystic Fibrosis …” published on October 27, 2016, Globenewswire.com published: “Concert Pharmaceuticals, Inc. (Nasdaq: CNCE) to Ring The Nasdaq Stock Market …” on October 24, 2016. More interesting news about Concert Pharmaceuticals Inc (NASDAQ:CNCE) were released by: Seekingalpha.com and their article: “Concert Pharmaceuticals: At 52 Week Lows With Upcoming Catalysts” published on October 18, 2016 as well as Businesswire.com‘s news article titled: “Concert Pharmaceuticals Expands Management Team” with publication date: September 06, 2016.
CNCE Company Profile
Concert Pharmaceuticals, Inc., incorporated on April 12, 2006, is a clinical-stage biopharmaceutical company. The Firm is engaged in the discovery and development of small molecule drugs. The Firm operates through the development of pharmaceutical products on its own behalf or in collaboration with others segment. The Firm has clinical candidates under development, including AVP-786, CTP-656, CTP-730 and JZP-386. The Company’s deuterated chemical entity platform (DCE Platform) enables it to identify compounds for deuteration and to design, evaluate, develop and manufacture deuterated compounds. The Firm is utilizing its DCE Platform to discover and develop product candidates for a range of indications.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.